Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer’s Bourla Defends Cancer Drug Pricing

This article was originally published in The Pink Sheet Daily

Executive Summary

“We should not discourage innovation right now,” Pfizer’s Group President of Vaccines, Oncology and Consumer Healthcare Albert Bourla said during a media briefing at the company headquarters.

Advertisement

Related Content

Pfizer Oncology Strategy: An Investment Starts To Pay Off
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
Roche Experimenting With New Pricing Models In Oncology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register